% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • jetmanbash jetmanbash Oct 20, 2010 9:30 PM Flag

    Prstate CA news from the FDA GnRN agonists:

    FDA confirms that it asked drug manufacturers to include warnings on risk for class of prostate cancer drugs
    The U.S. Food and Drug Administration today asked manufacturers to add new warnings to labeling of gonadotropin-releasing hormone (GnRH) agonists, a class of drugs primarily used to treat men with prostate cancer. The warnings would alert patients and their health care professionals to the potential risk of heart disease and diabetes in men treated with these medications. GnRH agnoists are marketed under the brand names: Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, and Zoladex. Several generic products are available. (SGEN, MIPI, RNN, OGXI, DNDN, ISIS, ISR, MYGN, MDVN, PFE, AZN)

    At least the market is getting the chance to recognize the symbols OGXI and ISIS. t

0.575-0.005(-0.88%)3:59 PMEDT